查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球注射給藥市場（按產品、劑型包裝、治療用途、使用模式、給藥部位、最終用戶和地區分類）- 預測至 2030 年
市場調查報告書
商品編碼
1732201

全球注射給藥市場（按產品、劑型包裝、治療用途、使用模式、給藥部位、最終用戶和地區分類）- 預測至 2030 年

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 967 Pages | 訂單完成後即時交付

價格

注射藥物輸送裝置市場預計將從 2025 年的 2,563 億美元成長到 2030 年的 3,737 億美元，預測期內的複合年成長率為 7.8%。

注射藥物輸送製劑市場預計將從 2025 年的 4,340 億美元成長到 2030 年的 6,611 億美元，預測期內的複合年成長率為 8.8%。

研究範圍
調查年份 2024-2030
基準年 2024
預測期 2024-2030
對價單位 金額（十億美元）
按細分市場 按產品、劑型包裝、治療用途、使用模式、給藥部位、最終用戶和地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

由於對以患者為中心、有針對性和微創治療解決方案的需求不斷增加，注射藥物傳輸市場正在經歷快速轉型。該市場的一個主要趨勢是轉向自動注射器、筆式注射器和穿戴式注射器等自行注射技術。這些進步提高了患者的依從性並促進了居家照護，這對於治療糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病尤其重要。

技術進步日益影響市場。具有連接功能、劑量追蹤和提醒系統的智慧注射器越來越受歡迎，反映了數位醫療的更廣泛趨勢。此外，微針和無針注射器的組合有助於減輕傳統注射器常帶來的疼痛和焦慮，特別是對於兒科和老年人。

製藥業越來越關注長效製劑、生物製藥和生物相似藥，這需要精確的輸送系統。這一趨勢正在鼓勵藥物開發商和設備製造商之間進行更緊密的合作。此外，監管機構正在更新其框架以更好地支持組合藥物，這有助於加快產品核可。

在注射藥物傳輸市場中，自行注射設備領域預計將在 2025 年至 2030 年期間實現最高成長率。這一成長是由全球向分散醫療保健的轉變、慢性病患病率的上升以及對患者自主權的日益重視所推動的。自動注射器包括自動注射器、筆式注射器和穿戴式注射器，提供便利性和準確性，同時減少對臨床環境的需求。因此它特別適合長期治療。

在美國和加拿大，生物製藥在治療自體免疫和代謝疾病方面的廣泛應用，加上優惠的報銷政策和數位技術在醫療保健領域的整合，推動著這一領域的成長。歐洲，特別是德國、法國和英國，由於老齡人口的成長和慢性病管理計劃的發展，需求正在顯著成長。在亞太地區，日本、中國和印度等國家由於醫療保健服務的改善、患者意識的提高以及生物相似藥供應的增加而經歷快速成長。

智慧連接功能、劑量記憶和疼痛緩解技術等技術趨勢使這些設備更具吸引力。 COVID-19 疫情也加速了自我護理的採用，因為病人往往不願意去醫院，而更喜歡在家治療。製藥公司和設備製造商之間的合作也在不斷增加，從而可以為注射療法提供客製化解決方案。總體而言，該領域的快速成長反映了臨床需求、患者偏好和技術進步的強大組合。

2024 年，安瓿瓶在注射藥物傳輸市場中貢獻了龐大的市場佔有率。安瓿瓶是該市場中成長最快的包裝類型，因為它具有卓越的無菌性、價格實惠且適用於多種藥物配方。安瓿瓶通常由玻璃或塑膠製成，非常適合儲存單劑量注射溶液，且沒有污染風險，在急性護理和醫院環境中非常受歡迎。

在印度、巴西和越南等新興經濟體中，安瓿瓶因其成本效益而被廣泛應用於政府疫苗接種計畫。此外，它與各種生技藥品和小分子藥物的兼容性促進了它在腫瘤學、抗感染疾病和荷爾蒙療法等治療領域的應用。

在人口、經濟和醫療保健等多種因素的共同推動下，亞太地區有望成為注射藥物輸送市場成長最快的地區。在中國和印度等大國，慢性病（尤其是糖尿病和癌症）的盛行率正在上升，推動了對先進注射療法的需求。此外，隨著生技藥品的取得管道不斷擴大，對自動注射器和筆式注射器等易於使用的設備的需求也日益成長。

在中國，政府的支持政策、不斷增加的研發投入以及蓬勃發展的生物技術產業正在刺激創新藥物輸送系統的應用。同時，學名藥市場成長的推動，印度的自動注射器和生物相似藥也呈現顯著成長。此外，越南和泰國等東南亞國家改善了醫療保健基礎設施和專科護理服務，從而刺激了該地區的需求。

都市化、可支配收入的增加和人口老化也推動了患者和醫療保健提供者尋求便捷的在家治療選擇的趨勢。此外，該地區的製造能力和具有成本效益的生產正在吸引全球製藥和醫療設備公司的合作。

本報告按產品、治療用途、配方、包裝、使用模式、給藥部位、最終用戶和地區對注射藥物輸送市場進行了研究。我們也研究影響市場成長的因素（市場促進因素和挑戰）。它分析了市場中的機會和挑戰，並詳細介紹了市場領導的競爭格局。此外，它還分析了微型市場的各自成長趨勢，並預測了六個主要地區及其各自國家的細分市場的收益。

該報告將幫助現有企業、新創企業或小型企業了解市場趨勢，並幫助他們佔領更大的市場佔有率。購買此報告的公司將能夠利用以下五種策略中的一種或多種：

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章重要考察

第5章市場概述

  • 市場動態
  • 產業趨勢
  • 影響客戶業務的趨勢/中斷
  • 定價分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
  • 投資金籌措場景
  • 技術分析
  • 專利分析
  • 貿易分析
  • 2025-2026 年重要會議與活動
  • 案例研究分析
  • 監管狀況
  • 波特五力分析
  • 主要相關人員和採購標準
  • 管道分析
  • 報銷分析
  • 未滿足的需求/最終用戶期望
  • 人工智慧/生成式人工智慧對注射藥物輸送市場的影響
  • 2025年美國關稅的影響

6. 注射給藥市場（依產品分類）

  • 介紹
  • 裝置
  • 配方

7. 注射藥物傳輸市場（以劑型包裝）

  • 介紹
  • 安瓿
  • 管瓶
  • 墨水匣
  • 瓶子

8. 注射給藥市場（依治療用途）

  • 介紹
  • 自體免疫疾病
  • 荷爾蒙失調
  • 肥胖
  • 癌症
  • 感染疾病
  • 罕見疾病
  • 其他

9. 注射給藥市場（依使用模式）

  • 介紹
  • 治療護理
  • 免疫
  • 其他

第10章。注射藥物輸送市場（按給藥部位）

  • 介紹
  • 經經皮給藥
  • 基於循環系統/肌肉骨骼的劑量
  • 基於器官的管理
  • 基於中樞神經系統的給藥

第 11 章。注射藥物輸送市場（按最終用戶分類）

  • 介紹
  • 醫院和診所
  • 居家照護
  • 長期照護環境
  • 養老院
  • 其他

第12章注射藥物傳輸市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 越南
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 中東和非洲宏觀經濟展望
    • 海灣合作理事會國家
    • 其他

第13章競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2020-2024年收益分析
  • 2024年市場佔有率分析
  • 品牌/產品比較
  • 主要企業研發支出
  • 估值和財務指標
  • 注射給藥裝置市場：公司估值矩陣（主要企業），2024 年
  • 注射給藥裝置市場：公司估值矩陣（Start-Ups/中小企業），2024 年
  • 注射給藥製劑市場：公司估值矩陣（主要企業），2024 年
  • 注射給藥製劑市場：公司估值矩陣（Start-Ups/中小企業），2023 年
  • 競爭場景

第14章公司概況-注射給藥裝置製造商

  • 主要參與企業
    • CARDINAL HEALTH
    • BD
    • B. BRAUN SE
    • BAXTER
    • TERUMO CORPORATION
    • PHILLIPS-MEDSIZE CORPORATION（MOLEX）
    • NIPRO
    • ICU MEDICAL, INC.
    • WEST PHARMACEUTICAL SERVICES, INC.
    • GERRESHEIMER AG
    • STEVANATO
    • SCHOTT PHARMA
    • MEDMIX
    • SOLM
    • YPSOMED
  • 其他公司
    • OWEN MUMFORD
    • HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
    • POLYMEDICURE
    • UNION MEDICO INC.
    • SHL MEDICAL
    • ELCAM MEDICAL

第15章公司簡介-注射藥物傳輸製劑製造商

  • 主要參與企業
    • JOHNSON & JOHNSON SERVICES, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • PFIZER INC.
    • MERCK & CO., INC.
    • NOVARTIS AG
    • BAYER AG
    • ASTRAZENECA
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED.
    • ELI LILLY AND COMPANY
    • AMGEN INC.
    • NOVO NORDISK A/S
    • REGENERON PHARMACEUTICALS INC.
    • FRESENIUS KABI AG
    • UCB SA
    • BIO-THERA SOLUTIONS, LTD.
  • 其他公司
    • SAGENT
    • VALNEVA SE
    • XERIS PHARMACEUTICALS, INC.
    • PHARMAESSENTIA CORPORATION
    • HERON THERAPEUTICS, INC.

第16章 附錄

Product Code: MD 3680

The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsBy Product, Therapeutic Application, Therapy Area, Formulation Packaging, Formulation Packaging, Usage Pattern, Site of Administration, End User, Region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis.

Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations.

The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals.

"By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period."

From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies.

In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars.

Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements.

"By formulation packaging, the ampoules segment accounted for the largest market share in 2024."

The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings.

In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies.

"The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period."

The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors.

In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand.

Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) * By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews: * By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%) * By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.

Reasons to Buy the Report

The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

  • Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS SEGMENTATION
    • 1.3.2 REGIONAL SEGMENTATION
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 INCLUSIONS AND EXCLUSIONS
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Breakdown of primaries
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
    • 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
    • 2.2.3 APPROACH 3: TOP-DOWN APPROACH
    • 2.2.4 APPROACH 4: BOTTOM-UP APPROACH
    • 2.2.5 APPROACH 4: PRIMARY INTERVIEWS
    • 2.2.6 APPROACH 5: DEMAND-SIDE APPROACH
    • 2.2.7 APPROACH 6: VOLUME DATA ANALYSIS
  • 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 STUDY ASSUMPTIONS
    • 2.5.2 GROWTH RATE ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW
  • 4.3 INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX
  • 4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
  • 4.5 INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

  • 5.1 MARKET DYNAMICS
    • 5.1.1 DRIVERS
      • 5.1.1.1 Growing demand for self-injection devices
      • 5.1.1.2 Advancements in drug delivery technologies
      • 5.1.1.3 Rising prevalence of chronic diseases
      • 5.1.1.4 Growing adoption of biologics and biosimilars
    • 5.1.2 RESTRAINTS
      • 5.1.2.1 Infections associated with needlestick injuries
      • 5.1.2.2 Stringent government regulations
    • 5.1.3 OPPORTUNITIES
      • 5.1.3.1 Development of novel drug delivery systems
      • 5.1.3.2 Growing preference for home-based care devices
      • 5.1.3.3 Growth opportunities in emerging economies
    • 5.1.4 CHALLENGES
      • 5.1.4.1 Alternative methods of drug delivery
      • 5.1.4.2 Complexities in developing wearable drug delivery systems
  • 5.2 INDUSTRY TRENDS
    • 5.2.1 REUSABLE DRUG DELIVERY DEVICES
    • 5.2.2 PREFILLED BIOLOGICS
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
      • 5.4.1.1 Average selling price trend of key players, by device type
      • 5.4.1.2 Average selling price trend of key players, by pen injectors
    • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
      • 5.4.2.1 Average selling price trend of pen injectors, by region
      • 5.4.2.2 Average selling price trend of needle-free injectors, by region
      • 5.4.2.3 Average selling price trend of autoinjectors, by region
      • 5.4.2.4 Average selling price trend of wearable injectors, by region
  • 5.5 VALUE CHAIN ANALYSIS
    • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.5.2 RAW MATERIAL PROCUREMENT
    • 5.5.3 MANUFACTURING
    • 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Autoinjectors and smart injection devices
      • 5.9.1.2 Needle-free injection systems and microneedle patches
      • 5.9.1.3 Wearable injectors for high-volume delivery
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Nanotechnology
      • 5.9.2.2 Biodegradable polymers
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Artificial intelligence and digital therapeutics
      • 5.9.3.2 Alternative routes of administration
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY
    • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE DATA FOR HS CODE 901890
      • 5.11.1.1 Import data
      • 5.11.1.2 Export data
    • 5.11.2 TRADE DATA FOR HS CODE 90183100
      • 5.11.2.1 Import data
      • 5.11.2.2 Export data
  • 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.13 CASE STUDY ANALYSIS
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 REGULATORY ANALYSIS
    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 PORTER'S FIVE FORCES ANALYSIS
    • 5.15.1 BARGAINING POWER OF SUPPLIERS
    • 5.15.2 BARGAINING POWER OF BUYERS
    • 5.15.3 THREAT OF NEW ENTRANTS
    • 5.15.4 THREAT OF SUBSTITUTES
    • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS
    • 5.16.2 BUYING CRITERIA
      • 5.16.2.1 Buying criteria for injectable drug delivery devices
      • 5.16.2.2 Buying criteria for injectable drug delivery devices with formulations
  • 5.17 PIPELINE ANALYSIS
  • 5.18 REIMBURSEMENT ANALYSIS
  • 5.19 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET
    • 5.20.1 INTRODUCTION
    • 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
    • 5.20.3 AI USE CASES
    • 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES
    • 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
  • 5.21 IMPACT OF 2025 US TARIFF
    • 5.21.1 INTRODUCTION
    • 5.21.2 KEY TARIFF RATES
    • 5.21.3 PRICE IMPACT ANALYSIS
    • 5.21.4 IMPACT ON COUNTRY/REGION
      • 5.21.4.1 North America
      • 5.21.4.2 Asia Pacific
      • 5.21.4.3 Europe
      • 5.21.4.4 Latin America
    • 5.21.5 IMPACT ON END-USE INDUSTRIES

6 INJECTABLE DRUG DELIVERY, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 DEVICES
    • 6.2.1 CONVENTIONAL INJECTION DEVICES
      • 6.2.1.1 By material
        • 6.2.1.1.1 Glass injectable devices
          • 6.2.1.1.1.1 Light protection, temperature resistance, and impermeability properties to drive market
        • 6.2.1.1.2 Plastic injectable devices
          • 6.2.1.1.2.1 Rapid increase in demand for syringes to aid growth
      • 6.2.1.2 By product
        • 6.2.1.2.1 Fillable syringes
          • 6.2.1.2.1.1 Ease of use and variable dosing formulations to boost market
        • 6.2.1.2.2 Prefilled syringes
          • 6.2.1.2.2.1 Minimal drug waste and low weight & space requirements to propel market
      • 6.2.1.3 By usability
        • 6.2.1.3.1 Reusable injection devices
          • 6.2.1.3.1.1 Cost-effective nature to contribute to growth
        • 6.2.1.3.2 Disposable injection devices
          • 6.2.1.3.2.1 Growing preference for ready-to-use devices to drive market
    • 6.2.2 SELF-INJECTION DEVICES
      • 6.2.2.1 Needle-free injectors
        • 6.2.2.1.1 By product
          • 6.2.2.1.1.1 Fillable needle-free injectors
          • 6.2.2.1.1.2 Prefilled needle-free injectors
        • 6.2.2.1.2 By technology
          • 6.2.2.1.2.1 Jet-based needle-free injectors
          • 6.2.2.1.2.2 Spring-based needle-free injectors
          • 6.2.2.1.2.3 Laser-powered needle-free injectors
          • 6.2.2.1.2.4 Vibration-based needle-free injectors
        • 6.2.2.1.3 By usability
          • 6.2.2.1.3.1 Reusable needle-free injectors
          • 6.2.2.1.3.2 Disposable needle-free injectors
      • 6.2.2.2 Autoinjectors
        • 6.2.2.2.1 By product
          • 6.2.2.2.1.1 Fillable autoinjectors
          • 6.2.2.2.1.2 Prefilled autoinjectors
        • 6.2.2.2.2 By technology
          • 6.2.2.2.2.1 Automated autoinjectors
          • 6.2.2.2.2.2 Manual autoinjectors
        • 6.2.2.2.3 By design
          • 6.2.2.2.3.1 Standardized autoinjectors
          • 6.2.2.2.3.2 Customized autoinjectors
        • 6.2.2.2.4 By usability
          • 6.2.2.2.4.1 Reusable autoinjectors
          • 6.2.2.2.4.2 Disposable autoinjectors
      • 6.2.2.3 Pen injectors
        • 6.2.2.3.1 By product
          • 6.2.2.3.1.1 Single-chambered pen injectors
          • 6.2.2.3.1.2 Double-chambered pen injectors.
        • 6.2.2.3.2 By design
          • 6.2.2.3.2.1 Standard pen injectors
          • 6.2.2.3.2.2 Customized pen injectors
        • 6.2.2.3.3 By usability
          • 6.2.2.3.3.1 Reusable pen injectors
          • 6.2.2.3.3.2 Disposable pen injectors
      • 6.2.2.4 Wearable injectors
        • 6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth
      • 6.2.2.5 Other self-injection devices
  • 6.3 FORMULATIONS
    • 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.3.1.1 Solutions
        • 6.3.1.1.1 High stability and sterility benefits to intensify growth
      • 6.3.1.2 Reconstituted/lyophilized formulations
        • 6.3.1.2.1 Higher suitability for parenteral administration to aid growth
      • 6.3.1.3 Suspensions
        • 6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth
      • 6.3.1.4 Emulsions
        • 6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market
    • 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.1 Colloidal dispersions
        • 6.3.2.1.1 Niosomes
          • 6.3.2.1.1.1 Low toxicity and economical features to speed up growth.
        • 6.3.2.1.2 Liposomes
          • 6.3.2.1.2.1 Flexible, biocompatible, and fully biodegradable properties to boost market
        • 6.3.2.1.3 Polymeric/mixed micelles
          • 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates to boost market
        • 6.3.2.1.4 Nanoparticles
          • 6.3.2.1.4.1 Solid-lipid nanoparticles
          • 6.3.2.1.4.2 Nanosuspensions
          • 6.3.2.1.4.3 Nanoemulsions
      • 6.3.2.2 Microparticles
        • 6.3.2.2.1 Microspheres
          • 6.3.2.2.1.1 Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market
        • 6.3.2.2.2 Microcapsules
          • 6.3.2.2.2.1 Higher biocompatibility properties to augment growth
    • 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
      • 6.3.3.1 Decreased side effects and overall medical cost reduction to advance growth

7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

  • 7.1 INTRODUCTION
  • 7.2 AMPOULES
    • 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH
  • 7.3 VIALS
    • 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH
  • 7.4 CARTRIDGES
    • 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH
  • 7.5 BOTTLES
    • 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH

8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 AUTOIMMUNE DISEASES
    • 8.2.1 RHEUMATOID ARTHRITIS
      • 8.2.1.1 Increased focus on early-stage diagnosis and treatment to amplify growth
    • 8.2.2 MULTIPLE SCLEROSIS
      • 8.2.2.1 Increasing target patient pool to contribute to growth
    • 8.2.3 CROHN'S DISEASE
      • 8.2.3.1 Rising use of liposomes to aid growth
    • 8.2.4 PSORIASIS
      • 8.2.4.1 Lifestyle changes and high disease prevalence to support growth
    • 8.2.5 OTHER AUTOIMMUNE DISEASES
  • 8.3 HORMONAL DISORDERS
    • 8.3.1 DIABETES
      • 8.3.1.1 Growing preference for self-injection devices over traditional syringes to drive market
    • 8.3.2 REPRODUCTIVE HEALTH DISEASES
      • 8.3.2.1 Lack of healthcare facilities and hygiene practices to aid growth
    • 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
      • 8.3.3.1 High efficacy and safety of heparin for antithrombotic therapy to aid growth
    • 8.3.4 OSTEOPOROSIS
      • 8.3.4.1 Increasing number of women with calcium and vitamin D deficiencies to foster growth
    • 8.3.5 GROWTH HORMONE DEFICIENCY
      • 8.3.5.1 Increased need for daily injections of recombinant human growth hormones to fuel market
  • 8.4 OBESITY
    • 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH
  • 8.5 CANCER
    • 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH
  • 8.6 INFECTIOUS DISEASES
    • 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET
  • 8.7 ORPHAN DISEASES
    • 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH
  • 8.8 OTHER THERAPEUTIC APPLICATIONS
    • 8.8.1 PAIN MANAGEMENT
      • 8.8.1.1 Growing focus on treating chronic pain to drive market
    • 8.8.2 ALLERGIES
      • 8.8.2.1 Increasing prevalence of asthma and eczema to promote growth
    • 8.8.3 AESTHETIC TREATMENTS
      • 8.8.3.1 Growing popularity of aesthetic procedures to propel market
    • 8.8.4 HEPATITIS C
      • 8.8.4.1 Need to curb virus spread due to needle reshare to sustain growth
    • 8.8.5 HEMOPHILIA
      • 8.8.5.1 Increasing need for preventive treatment plans to assist growth

9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN

  • 9.1 INTRODUCTION
  • 9.2 CURATIVE CARE
    • 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH
  • 9.3 IMMUNIZATION
    • 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET
  • 9.4 OTHER USAGE PATTERNS

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

  • 10.1 INTRODUCTION
  • 10.2 DERMAL-BASED ADMINISTRATION
    • 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH
  • 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
    • 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH
  • 10.4 ORGAN-BASED ADMINISTRATION
    • 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET
  • 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
    • 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH

11 INJECTABLE DRUG DELIVERY MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS & CLINICS
    • 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 11.3 HOME CARE SETTINGS
    • 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
  • 11.4 LONG-TERM CARE SETTINGS
    • 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH
  • 11.5 NURSING HOMES
    • 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH
  • 11.6 OTHER END USERS

12 INJECTABLE DRUG DELIVERY MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Increasing prevalence of chronic diseases to expedite growth
    • 12.2.3 CANADA
      • 12.2.3.1 Growing preference for self-injection devices to drive market
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 High healthcare spending to propel growth
    • 12.3.3 UK
      • 12.3.3.1 Rising cases of obesity and diabetes to promote growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Favorable health insurance system to accelerate growth
    • 12.3.5 SPAIN
      • 12.3.5.1 Favorable healthcare regulations support growth
    • 12.3.6 ITALY
      • 12.3.6.1 Regional variation in terms of coverage and benefits to hinder growth
    • 12.3.7 NETHERLANDS
      • 12.3.7.1 Growing focus on enhanced patient care to drive market
    • 12.3.8 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Large patient population and healthcare infrastructure improvements to augment growth
    • 12.4.3 JAPAN
      • 12.4.3.1 Supportive reimbursement policies and universal healthcare coverage to aid growth
    • 12.4.4 INDIA
      • 12.4.4.1 Rising diabetes and cardiovascular disease burden to propel market
    • 12.4.5 AUSTRALIA
      • 12.4.5.1 Increased patient volume to contribute to growth
    • 12.4.6 SOUTH KOREA
      • 12.4.6.1 Rising incidence of obesity and hypertension to amplify growth
    • 12.4.7 THAILAND
      • 12.4.7.1 Expanding self-administration options to support growth
    • 12.4.8 VIETNAM
      • 12.4.8.1 Rising investments and regulatory reforms to support market growth
    • 12.4.9 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Surge in obesity issues to stimulate growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Increasing incidence of chronic diseases to drive market
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Saudi Arabia
        • 12.6.2.1.1 Healthcare reforms to contribute to growth
      • 12.6.2.2 United Arab Emirates (UAE)
        • 12.6.2.2.1 Growing infrastructure investments to drive market
      • 12.6.2.3 Rest of GCC Countries
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.3 REVENUE ANALYSIS, 2020-2024
    • 13.3.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
    • 13.3.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
  • 13.4 MARKET SHARE ANALYSIS, 2024
    • 13.4.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
    • 13.4.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
  • 13.5 BRAND/PRODUCT COMPARISON
  • 13.6 R&D EXPENDITURE OF KEY PLAYERS
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 13.7.1 COMPANY VALUATION
    • 13.7.2 FINANCIAL METRICS
  • 13.8 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
    • 13.8.1 STARS
    • 13.8.2 EMERGING LEADERS
    • 13.8.3 PERVASIVE PLAYERS
    • 13.8.4 PARTICIPANTS
    • 13.8.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024
      • 13.8.5.1 Company footprint
      • 13.8.5.2 Region footprint
      • 13.8.5.3 Product type footprint
      • 13.8.5.4 Usage pattern footprint
      • 13.8.5.5 Therapeutic application footprint
      • 13.8.5.6 Site of administration footprint
  • 13.9 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
    • 13.9.1 PROGRESSIVE COMPANIES
    • 13.9.2 RESPONSIVE COMPANIES
    • 13.9.3 DYNAMIC COMPANIES
    • 13.9.4 STARTING BLOCKS
    • 13.9.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
      • 13.9.5.1 Detailed list of key startups/SMEs
      • 13.9.5.2 Competitive benchmarking of startups/SMES
  • 13.10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
    • 13.10.1 STARS
    • 13.10.2 EMERGING LEADERS
    • 13.10.3 PERVASIVE PLAYERS
    • 13.10.4 PARTICIPANTS
    • 13.10.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024
      • 13.10.5.1 Company footprint
      • 13.10.5.2 Region footprint
      • 13.10.5.3 Product type footprint
      • 13.10.5.4 Formulation packaging type footprint
      • 13.10.5.5 Therapeutic application footprint
      • 13.10.5.6 Site of administration footprint
  • 13.11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 13.11.1 PROGRESSIVE COMPANIES
    • 13.11.2 RESPONSIVE COMPANIES
    • 13.11.3 DYNAMIC COMPANIES
    • 13.11.4 STARTING BLOCKS
    • 13.11.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
      • 13.11.5.1 Detailed list of key startups/SMEs
      • 13.11.5.2 Competitive benchmarking of startups/SMEs
  • 13.12 COMPETITIVE SCENARIO
    • 13.12.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.12.2 DEALS
    • 13.12.3 EXPANSIONS

14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

  • 14.1 KEY PLAYERS
    • 14.1.1 CARDINAL HEALTH
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Expansions
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 BD
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Deals
        • 14.1.2.3.2 Expansions
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 B. BRAUN SE
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 MnM view
        • 14.1.3.3.1 Right to win
        • 14.1.3.3.2 Strategic choices
        • 14.1.3.3.3 Weaknesses and competitive threats
    • 14.1.4 BAXTER
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Right to win
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 TERUMO CORPORATION
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Expansions
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Right to win
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 PHILLIPS-MEDSIZE CORPORATION (MOLEX)
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches and approvals
        • 14.1.6.3.2 Deals
        • 14.1.6.3.3 Expansions
    • 14.1.7 NIPRO
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Expansions
    • 14.1.8 ICU MEDICAL, INC.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
    • 14.1.9 WEST PHARMACEUTICAL SERVICES, INC.
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
        • 14.1.9.3.2 Expansions
    • 14.1.10 GERRESHEIMER AG
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
        • 14.1.10.3.2 Deals
        • 14.1.10.3.3 Expansions
    • 14.1.11 STEVANATO
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Product launches and approvals
        • 14.1.11.3.2 Deals
        • 14.1.11.3.3 Expansions
    • 14.1.12 SCHOTT PHARMA
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Product launches and approvals
        • 14.1.12.3.2 Deals
        • 14.1.12.3.3 Expansions
    • 14.1.13 MEDMIX
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches and approvals
        • 14.1.13.3.2 Deals
    • 14.1.14 SOLM
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products offered
    • 14.1.15 YPSOMED
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Deals
        • 14.1.15.3.2 Expansions
  • 14.2 OTHER PLAYERS
    • 14.2.1 OWEN MUMFORD
    • 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
    • 14.2.3 POLYMEDICURE
    • 14.2.4 UNION MEDICO INC.
    • 14.2.5 SHL MEDICAL
    • 14.2.6 ELCAM MEDICAL

15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

  • 15.1 KEY PLAYERS
    • 15.1.1 JOHNSON & JOHNSON SERVICES, INC.
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Product launches and approvals
        • 15.1.1.3.2 Deals
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Right to win
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses and competitive threats
    • 15.1.2 F. HOFFMANN-LA ROCHE LTD
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Product launches and approvals
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Right to win
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses and competitive threats
    • 15.1.3 PFIZER INC.
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Product launches and approvals
        • 15.1.3.3.2 Deals
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Right to win
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses and competitive threats
    • 15.1.4 MERCK & CO., INC.
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Product launches and approvals
        • 15.1.4.3.2 Deals
        • 15.1.4.3.3 Expansions
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Right to win
        • 15.1.4.4.2 Strategic choices
        • 15.1.4.4.3 Weaknesses and competitive threats
    • 15.1.5 NOVARTIS AG
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Product launches and approvals
        • 15.1.5.3.2 Deals
        • 15.1.5.3.3 Expansions
      • 15.1.5.4 MnM view
        • 15.1.5.4.1 Right to win
        • 15.1.5.4.2 Strategic choices
        • 15.1.5.4.3 Weaknesses and competitive threats
    • 15.1.6 BAYER AG
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Product launches and approvals
        • 15.1.6.3.2 Expansions
    • 15.1.7 ASTRAZENECA
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Product launches and approvals
        • 15.1.7.3.2 Deals
        • 15.1.7.3.3 Expansions
    • 15.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Product launches and approvals
        • 15.1.8.3.2 Deals
        • 15.1.8.3.3 Expansions
    • 15.1.9 ELI LILLY AND COMPANY
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products offered
      • 15.1.9.3 Recent developments
        • 15.1.9.3.1 Product launches and approvals
        • 15.1.9.3.2 Expansions
    • 15.1.10 AMGEN INC.
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products offered
      • 15.1.10.3 Recent developments
        • 15.1.10.3.1 Product launches and approvals
        • 15.1.10.3.2 Deals
        • 15.1.10.3.3 Expansions
    • 15.1.11 NOVO NORDISK A/S
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
      • 15.1.11.3 Recent developments
        • 15.1.11.3.1 Product launches and approvals
        • 15.1.11.3.2 Deals
        • 15.1.11.3.3 Expansions
    • 15.1.12 REGENERON PHARMACEUTICALS INC.
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
        • 15.1.12.2.1 Product launches and approvals
        • 15.1.12.2.2 Deals
    • 15.1.13 FRESENIUS KABI AG
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products offered
      • 15.1.13.3 Recent developments
        • 15.1.13.3.1 Product launches and approvals
    • 15.1.14 UCB S.A.
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products offered
      • 15.1.14.3 Recent developments
        • 15.1.14.3.1 Product launches and approvals
    • 15.1.15 BIO-THERA SOLUTIONS, LTD.
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products offered
      • 15.1.15.3 Recent developments
        • 15.1.15.3.1 Product launches and approvals
  • 15.2 OTHER PLAYERS
    • 15.2.1 SAGENT
    • 15.2.2 VALNEVA SE
    • 15.2.3 XERIS PHARMACEUTICALS, INC.
    • 15.2.4 PHARMAESSENTIA CORPORATION
    • 15.2.5 HERON THERAPEUTICS, INC.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 RELATED REPORTS
  • 16.4 AUTHOR DETAILS

List of Tables

  • TABLE 1 INJECTABLE DRUG DELIVERY MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD), 2021-2024
  • TABLE 3 INJECTABLE DRUG DELIVERY MARKET: STUDY ASSUMPTIONS
  • TABLE 4 INJECTABLE DRUG DELIVERY MARKET: RISK ASSESSMENT
  • TABLE 5 APPROVALS FOR AUTOINJECTOR BIOLOGICS BY US FDA, 2024
  • TABLE 6 KEY DEVELOPMENTS IN PREFILLED SYRINGES AND PEN INJECTORS, 2024-2025
  • TABLE 7 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES
  • TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY DEVICE TYPE, 2022-2024 (USD)
  • TABLE 9 AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION, 2022-2024 (USD)
  • TABLE 10 AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION, 2022-2024 (USD)
  • TABLE 11 AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION, 2022-2024 (USD)
  • TABLE 12 AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION, 2022-2024 (USD)
  • TABLE 13 INJECTABLE DRUG DELIVERY DEVICE PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 14 INJECTABLE DRUG DELIVERY FORMULATION PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 15 INJECTABLE DRUG DELIVERY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023-2025
  • TABLE 16 IMPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 17 EXPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 18 IMPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 19 EXPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 20 INJECTABLE DRUG DELIVERY MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 21 CASE STUDY 1: DEVELOPMENT OF CLASS III DRUG DELIVERY SYSTEM FOR CHEMOTHERAPY
  • TABLE 22 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
  • TABLE 23 CASE STUDY 3: ADOPTION OF PEN INJECTOR PLATFORMS FOR IMPROVED THERAPEUTIC OUTCOMES
  • TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 29 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 30 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 32 INJECTABLE DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE, 2023-2027
  • TABLE 33 US ADJUSTED RECIPROCAL TARIFF RATES, 2024
  • TABLE 34 KEY PRODUCT-RELATED TARIFF EFFECTIVE INJECTABLE DRUG DELIVERY DEVICES
  • TABLE 35 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
  • TABLE 36 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
  • TABLE 37 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
  • TABLE 38 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
  • TABLE 39 INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 40 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 41 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES
  • TABLE 42 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 43 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 44 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES
  • TABLE 45 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 46 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 47 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 48 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 49 KEY PLAYERS PROVIDING GLASS INJECTABLE DEVICES
  • TABLE 50 GLASS INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 51 KEY PLAYERS PROVIDING PLASTIC INJECTABLE DEVICES
  • TABLE 52 PLASTIC INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 54 KEY PLAYERS PROVIDING FILLABLE SYRINGES
  • TABLE 55 FILLABLE SYRINGES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 56 KEY PLAYERS PROVIDING PREFILLED SYRINGES
  • TABLE 57 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES
  • TABLE 60 REUSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES
  • TABLE 62 DISPOSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 63 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES
  • TABLE 64 SELF-INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 65 SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 66 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 67 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS
  • TABLE 68 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 69 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 70 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 71 KEY PLAYERS PROVIDING FILLABLE NEEDLE-FREE INJECTORS
  • TABLE 72 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 73 KEY PLAYERS PROVIDING PREFILLED NEEDLE-FREE INJECTORS
  • TABLE 74 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 75 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 76 KEY PLAYERS PROVIDING JET-BASED NEEDLE-FREE INJECTORS
  • TABLE 77 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 78 KEY PLAYERS PROVIDING SPRING-BASED NEEDLE-FREE INJECTORS
  • TABLE 79 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 80 KEY PLAYERS PROVIDING LASER-POWERED NEEDLE-FREE INJECTORS
  • TABLE 81 LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 82 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 83 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 84 KEY PLAYERS PROVIDING REUSABLE NEEDLE-FREE INJECTORS
  • TABLE 85 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 86 KEY PLAYERS PROVIDING DISPOSABLE NEEDLE-FREE INJECTORS
  • TABLE 87 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 88 KEY PLAYERS PROVIDING AUTOINJECTORS
  • TABLE 89 AUTOINJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 90 AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 91 AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 92 KEY PLAYERS PROVIDING FILLABLE AUTOINJECTORS
  • TABLE 93 FILLABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 94 KEY PLAYERS PROVIDING PREFILLED AUTOINJECTORS
  • TABLE 95 PREFILLED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 96 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 97 KEY PLAYERS PROVIDING AUTOMATED AUTOINJECTORS
  • TABLE 98 AUTOMATED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 99 KEY PLAYERS PROVIDING MANUAL AUTOINJECTORS
  • TABLE 100 MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 101 AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 102 KEY PLAYERS PROVIDING STANDARDIZED AUTOINJECTORS
  • TABLE 103 STANDARDIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 104 KEY PLAYERS PROVIDING CUSTOMIZED AUTOINJECTORS
  • TABLE 105 CUSTOMIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 106 AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 107 KEY PLAYERS PROVIDING REUSABLE AUTOINJECTORS
  • TABLE 108 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 109 KEY PLAYERS PROVIDING DISPOSABLE AUTOINJECTORS
  • TABLE 110 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 111 KEY PLAYERS PROVIDING PEN INJECTORS
  • TABLE 112 PEN INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 113 PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 114 PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 115 KEY PLAYERS PROVIDING SINGLE-CHAMBERED PEN INJECTORS
  • TABLE 116 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 117 KEY PLAYERS PROVIDING DOUBLE-CHAMBERED PEN INJECTORS
  • TABLE 118 DOUBLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 119 PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 120 KEY PLAYERS PROVIDING STANDARD PEN INJECTORS
  • TABLE 121 STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 122 KEY PLAYERS PROVIDING CUSTOMIZED PEN INJECTORS
  • TABLE 123 CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 124 PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 125 KEY PLAYERS PROVIDING REUSABLE PEN INJECTORS
  • TABLE 126 REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 127 KEY PLAYERS PROVIDING DISPOSABLE PEN INJECTORS
  • TABLE 128 DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 129 KEY PLAYERS PROVIDING WEARABLE INJECTORS
  • TABLE 130 WEARABLE INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 131 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 132 KEY PLAYERS PROVIDING OTHER SELF-INJECTION DEVICES
  • TABLE 133 OTHER SELF-INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 134 OTHER SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 135 KEY PLAYERS PROVIDING FORMULATIONS
  • TABLE 136 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 137 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 138 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS
  • TABLE 139 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 140 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 141 KEY PLAYERS PROVIDING SOLUTIONS
  • TABLE 142 INJECTABLE DRUG DELIVERY SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 143 KEY PLAYERS PROVIDING RECONSTITUTED/LYOPHILIZED FORMULATIONS
  • TABLE 144 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 145 KEY PLAYERS PROVIDING SUSPENSIONS
  • TABLE 146 INJECTABLE DRUG DELIVERY SUSPENSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 147 KEY PLAYERS PROVIDING EMULSIONS
  • TABLE 148 INJECTABLE DRUG DELIVERY EMULSIONS MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 149 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS
  • TABLE 150 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 151 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 152 KEY PLAYERS PROVIDING COLLOIDAL DISPERSIONS
  • TABLE 153 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 154 COLLOIDAL DISPERSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 155 INJECTABLE DRUG DELIVERY NIOSOMES MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 156 KEY PLAYERS PROVIDING LIPOSOMES
  • TABLE 157 INJECTABLE DRUG DELIVERY LIPOSOMES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 158 KEY PLAYERS PROVIDING POLYMERIC/MIXED MICELLES
  • TABLE 159 INJECTABLE DRUG DELIVERY POLYMERIC/MIXED MICELLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 160 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 161 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 162 KEY PLAYERS PROVIDING SOLID-LIPID NANOPARTICLES
  • TABLE 163 INJECTABLE DRUG DELIVERY SOLID-LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 164 KEY PLAYERS PROVIDING NANOSUSPENSIONS
  • TABLE 165 INJECTABLE DRUG DELIVERY NANOSUSPENSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 166 KEY PLAYERS PROVIDING NANOEMULSIONS
  • TABLE 167 INJECTABLE DRUG DELIVERY NANOEMULSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 168 KEY PLAYERS PROVIDING MICROPARTICLES
  • TABLE 169 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 170 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 171 KEY PLAYERS PROVIDING MICROSPHERES
  • TABLE 172 INJECTABLE DRUG DELIVERY MICROSPHERES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 173 KEY PLAYERS PROVIDING MICROCAPSULES
  • TABLE 174 INJECTABLE DRUG DELIVERY MICROCAPSULES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 175 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS
  • TABLE 176 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 177 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 178 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 179 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 180 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 181 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 182 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 183 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AUTOIMMUNE DISEASES
  • TABLE 184 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 185 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 186 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR RHEUMATOID ARTHRITIS
  • TABLE 187 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 188 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR MULTIPLE SCLEROSIS
  • TABLE 189 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 190 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CROHN'S DISEASE
  • TABLE 191 INJECTABLE DRUG DELIVERY MARKET FOR CROHN'S DISEASE, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 192 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PSORIASIS
  • TABLE 193 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 194 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER AUTOIMMUNE DISEASES
  • TABLE 195 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 196 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HORMONAL DISORDERS
  • TABLE 197 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 198 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 199 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR DIABETES
  • TABLE 200 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 201 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR REPRODUCTIVE HEALTH DISEASES
  • TABLE 202 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 203 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
  • TABLE 204 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 205 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OSTEOPOROSIS
  • TABLE 206 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 207 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR GROWTH HORMONE DEFICIENCY
  • TABLE 208 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 209 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OBESITY
  • TABLE 210 INJECTABLE DRUG DELIVERY MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 211 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CANCER
  • TABLE 212 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 213 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR INFECTIOUS DISEASES
  • TABLE 214 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 215 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ORPHAN DISEASES
  • TABLE 216 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 217 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER THERAPEUTIC APPLICATIONS
  • TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 219 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PAIN MANAGEMENT
  • TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 221 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ALLERGIES
  • TABLE 222 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 223 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AESTHETIC TREATMENTS
  • TABLE 224 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 225 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEPATITIS C
  • TABLE 226 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 227 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEMOPHILIA
  • TABLE 228 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 229 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 230 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 231 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 232 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 233 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 234 KEY PLAYERS PROVIDING DERMAL-BASED ADMINISTRATION
  • TABLE 235 INJECTABLE DRUG DELIVERY MARKET FOR DERMAL-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 236 KEY PLAYERS PROVIDING CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
  • TABLE 237 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 238 KEY PLAYERS PROVIDING ORGAN-BASED ADMINISTRATION
  • TABLE 239 INJECTABLE DRUG DELIVERY MARKET FOR ORGAN-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 240 KEY PLAYERS PROVIDING CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
  • TABLE 241 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 242 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 243 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 244 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 245 INJECTABLE DRUG DELIVERY MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 246 INJECTABLE DRUG DELIVERY MARKET FOR NURSING HOMES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 247 INJECTABLE DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 248 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 249 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 250 NORTH AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 251 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 252 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 253 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 254 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 255 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 256 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 257 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 258 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 259 NORTH AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 260 NORTH AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 262 NORTH AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 263 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 264 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 265 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 266 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 267 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 268 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 269 NORTH AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 270 NORTH AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 271 NORTH AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 272 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 273 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 274 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 275 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 276 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 277 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 278 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 279 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 280 US: KEY MACROECONOMIC INDICATORS
  • TABLE 281 US: INJECTABLE DRUG DELIVERY MARKET PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 282 US: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 283 US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 284 US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 285 US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 286 US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 287 US: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 288 US: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 289 US: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 290 US: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 291 US: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 292 US: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 293 US: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 294 US: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 295 US: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 296 US: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 297 US: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 298 US: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 299 US: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 300 US: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 301 US: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 302 US: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 303 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 304 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 305 US: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 306 US: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 307 US: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 308 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 309 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 310 US: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 311 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 312 CANADA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 313 CANADA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 314 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 315 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 316 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 317 CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 318 CANADA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 319 CANADA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 320 CANADA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 321 CANADA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 322 CANADA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 323 CANADA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 324 CANADA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 325 CANADA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 326 CANADA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 327 CANADA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 328 CANADA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 329 CANADA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 330 CANADA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 331 CANADA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 332 CANADA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 333 CANADA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 334 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 335 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 336 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 337 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 338 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 339 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 340 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 341 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 342 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 343 EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 344 EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 345 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 346 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 347 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 348 EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 349 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 350 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 351 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 352 EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 353 EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 354 EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 355 EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 356 EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 357 EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 358 EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 359 EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 360 EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 361 EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 362 EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 363 EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 364 EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 365 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 366 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 367 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 368 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 369 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 370 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 371 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 372 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 373 GERMANY: KEY MACROECONOMIC INDICATORS
  • TABLE 374 GERMANY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 375 GERMANY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 376 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 377 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 378 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 379 GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 380 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 381 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 382 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 383 GERMANY: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 384 GERMANY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 385 GERMANY: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 386 GERMANY: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 387 GERMANY: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 388 GERMANY: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 389 GERMANY: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 390 GERMANY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 391 GERMANY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 392 GERMANY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 393 GERMANY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 394 GERMANY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 395 GERMANY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 396 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 397 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 398 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 399 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 400 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 401 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 402 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 403 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 404 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 405 UK: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 406 UK: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 407 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 408 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 409 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 410 UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 411 UK: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 412 UK: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 413 UK: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 414 UK: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 415 UK: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 416 UK: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 417 UK: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 418 UK: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 419 UK: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 420 UK: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 421 UK: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 422 UK: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 423 UK: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 424 UK: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 425 UK: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 426 UK: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 427 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 428 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 429 UK: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 430 UK: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 431 UK: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 432 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 433 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 434 UK: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 435 FRANCE: KEY MACROECONOMIC INDICATORS
  • TABLE 436 FRANCE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 437 FRANCE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 438 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 439 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 440 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 441 FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 442 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 443 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 444 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 445 FRANCE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 446 FRANCE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 447 FRANCE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 448 FRANCE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 449 FRANCE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 450 FRANCE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 451 FRANCE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 452 FRANCE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 453 FRANCE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 454 FRANCE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 455 FRANCE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 456 FRANCE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 457 FRANCE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 458 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 459 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 460 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 461 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 462 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 463 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 464 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 465 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 466 SPAIN: KEY MACROECONOMIC INDICATORS
  • TABLE 467 SPAIN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 468 SPAIN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 469 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 470 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 471 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 472 SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 473 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 474 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 475 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 476 SPAIN: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 477 SPAIN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 478 SPAIN: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 479 SPAIN: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 480 SPAIN: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 481 SPAIN: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 482 SPAIN: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 483 SPAIN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 484 SPAIN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 485 SPAIN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 486 SPAIN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 487 SPAIN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 488 SPAIN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 489 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 490 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 491 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 492 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 493 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 494 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 495 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 496 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 497 ITALY: KEY MACROECONOMIC INDICATORS
  • TABLE 498 ITALY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 499 ITALY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 500 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 501 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 502 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 503 ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 504 ITALY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 505 ITALY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 506 ITALY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 507 ITALY: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 508 ITALY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 509 ITALY: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 510 ITALY: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 511 ITALY: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 512 ITALY: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 513 ITALY: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 514 ITALY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 515 ITALY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 516 ITALY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 517 ITALY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 518 ITALY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 519 ITALY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 520 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 521 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 522 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 523 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 524 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 525 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 526 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 527 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 528 NETHERLANDS: KEY MACROECONOMIC INDICATORS
  • TABLE 529 NETHERLANDS: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 530 NETHERLANDS: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 531 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 532 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 533 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 534 NETHERLANDS: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 535 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 536 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 537 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 538 NETHERLANDS: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 539 NETHERLANDS: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 540 NETHERLANDS: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 541 NETHERLANDS: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 542 NETHERLANDS: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 543 NETHERLANDS: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 544 NETHERLANDS: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 545 NETHERLANDS: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 546 NETHERLANDS: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 547 NETHERLANDS: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 548 NETHERLANDS: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 549 NETHERLANDS: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 550 NETHERLANDS: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 551 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 552 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 553 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 554 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 555 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 556 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 557 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 558 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 559 REST OF EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 560 REST OF EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 561 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 562 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 563 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 564 REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 565 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 566 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 567 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 568 REST OF EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 569 REST OF EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 570 REST OF EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 571 REST OF EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 572 REST OF EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 573 REST OF EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 574 REST OF EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 575 REST OF EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 576 REST OF EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 577 REST OF EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 578 REST OF EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 579 REST OF EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 580 REST OF EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 581 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 582 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 583 REST OF EUROPE: INJECTABLE DRUG DELIVERY FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 584 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 585 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 586 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 587 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 588 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 589 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 590 ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 591 ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 592 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 593 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 594 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 595 ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 596 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 597 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 598 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 599 ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 600 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 601 ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 602 ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 603 ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 604 ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 605 ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 606 ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 607 ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 608 ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 609 ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 610 ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 611 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 612 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 613 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 614 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 615 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 616 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 617 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 618 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 619 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 620 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 621 CHINA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 622 CHINA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 623 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 624 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 625 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 626 CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 627 CHINA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 628 CHINA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 629 CHINA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 630 CHINA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 631 CHINA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 632 CHINA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 633 CHINA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 634 CHINA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 635 CHINA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 636 CHINA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 637 CHINA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 638 CHINA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 639 CHINA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 640 CHINA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 641 CHINA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 642 CHINA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 643 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 644 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 645 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 646 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 647 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 648 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 649 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 650 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 651 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 652 JAPAN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 653 JAPAN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 654 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 655 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 656 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 657 JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 658 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 659 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 660 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 661 JAPAN: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 662 JAPAN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 663 JAPAN: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 664 JAPAN: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 665 JAPAN: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 666 JAPAN: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 667 JAPAN: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 668 JAPAN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 669 JAPAN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 670 JAPAN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 671 JAPAN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 672 JAPAN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 673 JAPAN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 674 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 675 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 676 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 677 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 678 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 679 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 680 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 681 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 682 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 683 INDIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 684 INDIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 685 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 686 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 687 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 688 INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 689 INDIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 690 INDIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 691 INDIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 692 INDIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 693 INDIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 694 INDIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 695 INDIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 696 INDIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 697 INDIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 698 INDIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 699 INDIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 700 INDIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 701 INDIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 702 INDIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 703 INDIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 704 INDIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 705 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 706 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 707 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 708 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 709 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 710 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 711 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 712 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 713 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 714 AUSTRALIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 715 AUSTRALIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 716 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 717 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 718 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 719 AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 720 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 721 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 722 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 723 AUSTRALIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 724 AUSTRALIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 725 AUSTRALIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 726 AUSTRALIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 727 AUSTRALIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 728 AUSTRALIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 729 AUSTRALIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 730 AUSTRALIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 731 AUSTRALIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 732 AUSTRALIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 733 AUSTRALIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 734 AUSTRALIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 735 AUSTRALIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 736 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 737 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 738 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 739 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 740 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 741 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 742 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 743 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 744 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
  • TABLE 745 SOUTH KOREA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, TYPE, 2023-2030 (USD BILLION)
  • TABLE 746 SOUTH KOREA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 747 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 748 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 749 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 750 SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 751 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 752 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 753 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 754 SOUTH KOREA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 755 SOUTH KOREA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 756 SOUTH KOREA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 757 SOUTH KOREA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 758 SOUTH KOREA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 759 SOUTH KOREA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 760 SOUTH KOREA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 761 SOUTH KOREA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 762 SOUTH KOREA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 763 SOUTH KOREA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 764 SOUTH KOREA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 765 SOUTH KOREA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 766 SOUTH KOREA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 767 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 768 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 769 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 770 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 771 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 772 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 773 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 774 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 775 THAILAND: KEY MACROECONOMIC INDICATORS
  • TABLE 776 THAILAND: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 777 THAILAND: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 778 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 779 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 780 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 781 THAILAND: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 782 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 783 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 784 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 785 THAILAND: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 786 THAILAND: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 787 THAILAND: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 788 THAILAND: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 789 THAILAND: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 790 THAILAND: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 791 THAILAND: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 792 THAILAND: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 793 THAILAND: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 794 THAILAND: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 795 THAILAND: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 796 THAILAND: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 797 THAILAND: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 798 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 799 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 800 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 801 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 802 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 803 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 804 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 805 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 806 VIETNAM: KEY MACROECONOMIC INDICATORS
  • TABLE 807 VIETNAM: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 808 VIETNAM: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 809 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 810 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 811 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 812 VIETNAM: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 813 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 814 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 815 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 816 VIETNAM: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 817 VIETNAM: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 818 VIETNAM: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 819 VIETNAM: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 820 VIETNAM: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 821 VIETNAM: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 822 VIETNAM: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 823 VIETNAM: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 824 VIETNAM: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 825 VIETNAM: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 826 VIETNAM: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 827 VIETNAM: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 828 VIETNAM: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 829 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 830 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 831 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 832 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 833 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 834 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 835 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 836 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 837 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 838 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 839 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 840 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 841 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 842 REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 843 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 844 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 845 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 846 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 847 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 848 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 849 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 850 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 851 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 852 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 853 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 854 REST OF ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 855 REST OF ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 856 REST OF ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 857 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 858 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 859 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 860 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 861 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 862 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 863 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 864 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 865 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 866 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 867 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 868 LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 869 LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 870 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 871 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 872 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 873 LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 874 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 875 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 876 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 877 LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 878 LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 879 LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 880 LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 881 LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 882 LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 883 LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 884 LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 885 LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 886 LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 887 LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 888 LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 889 LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 890 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 891 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 892 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 893 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 894 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 895 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 896 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 897 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 898 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 899 BRAZIL: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 900 BRAZIL: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 901 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 902 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 903 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 904 BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 905 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 906 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 907 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 908 BRAZIL: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 909 BRAZIL: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 910 BRAZIL: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 911 BRAZIL: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 912 BRAZIL: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 913 BRAZIL: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 914 BRAZIL: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 915 BRAZIL: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 916 BRAZIL: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 917 BRAZIL: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 918 BRAZIL: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 919 BRAZIL: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 920 BRAZIL: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 921 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 922 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 923 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 924 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 925 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 926 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 927 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 928 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 929 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 930 MEXICO: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 931 MEXICO: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 932 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 933 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 934 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 935 MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 936 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 937 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 938 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 939 MEXICO: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 940 MEXICO: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 941 MEXICO: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 942 MEXICO: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 943 MEXICO: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 944 MEXICO: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 945 MEXICO: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 946 MEXICO: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 947 MEXICO: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 948 MEXICO: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 949 MEXICO: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 950 MEXICO: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 951 MEXICO: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 952 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 953 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 954 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 955 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 956 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 957 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 958 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 959 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 960 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 961 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 962 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 963 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 964 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 965 REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 966 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 967 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 968 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 969 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 970 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 971 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 972 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 973 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 974 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 975 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 976 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 977 REST OF LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 978 REST OF LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 979 REST OF LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 980 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 981 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 982 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 983 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 984 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 985 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 986 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 987 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 988 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 989 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 990 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 991 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 992 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 993 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 994 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 995 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 996 MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 997 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 998 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 999 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1000 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1001 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1002 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1003 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1004 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1005 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1006 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1007 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1008 MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1009 MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1010 MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1011 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1012 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1013 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1014 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1015 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1016 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1017 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1018 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1019 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1020 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1021 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 1022 GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1023 GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1024 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 1025 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1026 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1027 GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1028 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1029 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1030 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1031 GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1032 GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1033 GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1034 GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1035 GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1036 GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1037 GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1038 GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1039 GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1040 GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1041 GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1042 GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1043 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1044 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1045 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1046 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1047 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1048 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1049 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1050 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1051 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1052 SAUDI ARABIA: KEY MACROECONOMIC INDICATORS
  • TABLE 1053 SAUDI ARABIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1054 SAUDI ARABIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1055 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 1056 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1057 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1058 SAUDI ARABIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1059 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1060 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1061 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1062 SAUDI ARABIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1063 SAUDI ARABIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1064 SAUDI ARABIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1065 SAUDI ARABIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1066 SAUDI ARABIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1067 SAUDI ARABIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1068 SAUDI ARABIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1069 SAUDI ARABIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1070 SAUDI ARABIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1071 SAUDI ARABIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1072 SAUDI ARABIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1073 SAUDI ARABIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1074 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1075 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1076 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1077 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1078 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1079 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1080 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1081 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1082 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1083 UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS
  • TABLE 1084 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1085 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1086 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 1087 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1088 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1089 UNITED ARAB EMIRATES (UAE): SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1090 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1091 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1092 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1093 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1094 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1095 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1096 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1097 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1098 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1099 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1100 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1101 UNITED ARAB EMIRATES (UAE): CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1102 UNITED ARAB EMIRATES (UAE): NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1103 UNITED ARAB EMIRATES (UAE): COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1104 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1105 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1106 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1107 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1108 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1109 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1110 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1111 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1112 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1113 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1114 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1115 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1116 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 1117 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1118 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1119 REST OF GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1120 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1121 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1122 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1123 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1124 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1125 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1126 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1127 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1128 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1129 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1130 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1131 REST OF GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1132 REST OF GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1133 REST OF GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1134 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1135 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1136 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1137 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1138 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1139 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1140 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1141 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1142 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1144 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1145 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1146 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
  • TABLE 1147 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1148 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1149 REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1150 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1151 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1152 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1153 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1154 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
  • TABLE 1155 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1156 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1157 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 1158 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
  • TABLE 1159 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
  • TABLE 1160 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1161 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1162 REST OF MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1163 REST OF MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1164 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1165 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1166 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
  • TABLE 1167 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 1168 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1169 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1170 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 1171 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
  • TABLE 1172 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
  • TABLE 1173 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 1174 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET
  • TABLE 1175 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION
  • TABLE 1176 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION
  • TABLE 1177 INJECTABLE DRUG DELIVERY DEVICES MARKET: REGION FOOTPRINT
  • TABLE 1178 INJECTABLE DRUG DELIVERY DEVICES MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 1179 INJECTABLE DRUG DELIVERY DEVICES MARKET: USAGE PATTERN FOOTPRINT
  • TABLE 1180 INJECTABLE DRUG DELIVERY DEVICES MARKET: THERAPEUTIC APPLICATION FOOTPRINT
  • TABLE 1181 INJECTABLE DRUG DELIVERY DEVICES MARKET: SITE OF ADMINISTRATION FOOTPRINT
  • TABLE 1182 INJECTABLE DRUG DELIVERY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 1183 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 1184 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: REGION FOOTPRINT
  • TABLE 1185 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 1186 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: FORMULATION PACKAGING FOOTPRINT
  • TABLE 1187 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: THERAPEUTIC APPLICATION FOOTPRINT
  • TABLE 1188 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: SITE OF ADMINISTRATION TYPE FOOTPRINT
  • TABLE 1189 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 1190 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 1191 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1192 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1193 INJECTABLE DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1194 CARDINAL HEALTH: COMPANY OVERVIEW
  • TABLE 1195 CARDINAL HEALTH: PRODUCTS OFFERED
  • TABLE 1196 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1197 BD: COMPANY OVERVIEW
  • TABLE 1198 BD: PRODUCTS OFFERED
  • TABLE 1199 BD: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1200 BD: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1201 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 1202 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 1203 BAXTER: COMPANY OVERVIEW
  • TABLE 1204 BAXTER: PRODUCTS OFFERED
  • TABLE 1205 BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1206 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 1207 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 1208 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1209 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1210 PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW
  • TABLE 1211 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED
  • TABLE 1212 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1213 PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1214 PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1215 NIPRO: COMPANY OVERVIEW
  • TABLE 1216 NIPRO: PRODUCTS OFFERED
  • TABLE 1217 NIPRO: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1218 ICU MEDICAL, INC.: COMPANY OVERVIEW
  • TABLE 1219 ICU MEDICAL, INC.: PRODUCTS OFFERED
  • TABLE 1220 ICU MEDICAL, INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1221 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 1222 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 1223 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1224 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1225 GERRESHEIMER AG: COMPANY OVERVIEW
  • TABLE 1226 GERRESHEIMER AG: PRODUCTS OFFERED
  • TABLE 1227 GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1228 GERRESHMEIMER AG: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1229 GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1230 STEVANATO: COMPANY OVERVIEW
  • TABLE 1231 STEVANATO: PRODUCTS OFFERED
  • TABLE 1232 STEVANATO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1233 STEVANATO: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1234 STEVANATO: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1235 SCHOTT PHARMA: COMPANY OVERVIEW
  • TABLE 1236 SCHOTT PHARMA: PRODUCTS OFFERED
  • TABLE 1237 SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1238 SCHOTT PHARMA: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1239 SCOTT PHARMA: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1240 MEDMIX: COMPANY OVERVIEW
  • TABLE 1241 MEDMIX: PRODUCTS OFFERED
  • TABLE 1242 MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
  • TABLE 1243 MEDMIX: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1244 SOLM: COMPANY OVERVIEW
  • TABLE 1245 SOLM: PRODUCTS OFFERED
  • TABLE 1246 YPSOMED: COMPANY OVERVIEW
  • TABLE 1247 YPSOMED: PRODUCTS OFFERED
  • TABLE 1248 YPSOMED: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 1249 YPSOMED: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 1250 OWEN MUMFORD: COMPANY OVERVIEW
  • TABLE 1251 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW
  • TABLE 1252 POLYMEDICURE: COMPANY OVERVIEW
  • TABLE 1253 UNION MEDICO INC.: COMPANY OVERVIEW
  • TABLE 1254 SHL MEDICAL: COMPANY OVERVIEW
  • TABLE 1255 ELCAM MEDICAL: COMPANY OVERVIEW
  • TABLE 1256 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 1257 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 1258 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1259 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1260 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 1261 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 1262 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1263 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 1264 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 1265 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1266 PFIZER INC.: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1267 MERCK & CO., INC.: COMPANY OVERVIEW
  • TABLE 1268 MERCK & CO., INC.: PRODUCTS OFFERED
  • TABLE 1269 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1270 MERCK & CO., INC.: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1271 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1272 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 1273 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 1274 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1275 NOVARTIS AG: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1276 NOVARTIS AG: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1277 BAYER AG: COMPANY OVERVIEW
  • TABLE 1278 BAYER AG: PRODUCTS OFFERED
  • TABLE 1279 BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1280 BAYER AG: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1281 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 1282 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 1283 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1284 ASTRAZENECA: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1285 ASTRAZENECA: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1286 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
  • TABLE 1287 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
  • TABLE 1288 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1289 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1290 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1291 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 1292 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 1293 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1294 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1295 AMGEN INC.: COMPANY OVERVIEW
  • TABLE 1296 AMGEN INC.: PRODUCTS OFFERED
  • TABLE 1297 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1298 AMGEN INC.: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1299 AMGEN INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1300 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 1301 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 1302 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1303 NOVO NORDISK A/S: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1304 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 1305 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 1306 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
  • TABLE 1307 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1308 REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022-APRIL 2025
  • TABLE 1309 FRESENIUS KABI AG: COMPANY OVERVIEW
  • TABLE 1310 FRESENIUS KABI AG: PRODUCTS OFFERED
  • TABLE 1311 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1312 UCB S.A.: COMPANY OVERVIEW
  • TABLE 1313 UCB S.A.: PRODUCTS OFFERED
  • TABLE 1314 UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1315 BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW
  • TABLE 1316 BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED
  • TABLE 1317 BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
  • TABLE 1318 SAGENT: COMPANY OVERVIEW
  • TABLE 1319 VALNEVA SE: COMPANY OVERVIEW
  • TABLE 1320 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 1321 PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW
  • TABLE 1322 HERON THERAPEUTICS, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 2 INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION
  • FIGURE 3 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 8 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 BOTTOM-UP APPROACH
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
  • FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 14 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 15 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2025 VS. 2030 (USD BILLION)
  • FIGURE 16 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 19 RISING CHRONIC DISEASES TO DRIVE MARKET
  • FIGURE 20 DEVICES SEGMENT AND US DOMINATED NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET IN 2024
  • FIGURE 21 ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 23 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 24 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 26 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS (INSULIN PENS), 2024 (USD)
  • FIGURE 27 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 INJECTABLE DRUG DELIVERY MARKET: INVESTMENT AND FUNDING SCENARIO, 2021-2023
  • FIGURE 31 INJECTABLE DRUG DELIVERY MARKET: PATENT ANALYSIS, JANUARY 2014-MARCH 2025
  • FIGURE 32 TOP APPLICANTS FOR INJECTABLE DRUG DELIVERY PATENTS, JANUARY 2014-MARCH 2025
  • FIGURE 33 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS & CLINICS (INJECTABLE DRUG DELIVERY DEVICES)
  • FIGURE 35 BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES FOR TOP THREE END USERS
  • FIGURE 36 KEY BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY WITH FORMULATIONS FOR TOP THREE END USERS
  • FIGURE 37 TOTAL NUMBER OF TRIALS COMPLETED/YEAR, 2024-2032
  • FIGURE 38 AI USE CASES
  • FIGURE 39 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT, 2024
  • FIGURE 40 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 42 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2022-2024
  • FIGURE 43 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2022-2024
  • FIGURE 44 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
  • FIGURE 45 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
  • FIGURE 46 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
  • FIGURE 47 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
  • FIGURE 48 INJECTABLE DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET, 2022-2024
  • FIGURE 50 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 51 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 52 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 53 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 54 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 55 INJECTABLE DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX, 2024
  • FIGURE 56 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT
  • FIGURE 57 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 58 CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
  • FIGURE 59 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 60 B. BRAUN SE: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BAXTER: COMPANY SNAPSHOT (2024)
  • FIGURE 62 TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 63 NIPRO: COMPANY SNAPSHOT (2024)
  • FIGURE 64 ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 65 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 66 GERRESHEIMER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 67 STEVANATO: COMPANY SNAPSHOT (2024)
  • FIGURE 68 SCHOTT PHARMA: COMPANY SNAPSHOT (2024)
  • FIGURE 69 MEDMIX: COMPANY SNAPSHOT (2024)
  • FIGURE 70 YPSOMED: COMPANY SNAPSHOT (2024)
  • FIGURE 71 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 72 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
  • FIGURE 73 PFIZER INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 74 MERCK & CO., INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 75 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 76 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 77 ASTRAZENECA: COMPANY SNAPSHOT (2024)
  • FIGURE 78 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 79 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
  • FIGURE 80 AMGEN INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 81 NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)
  • FIGURE 82 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 83 FRESENIUS KABI AG: COMPANY SNAPSHOT (2024)
  • FIGURE 84 UCB S.A.: COMPANY SNAPSHOT (2024)
  • FIGURE 85 BIO-THERA SOLUTIONS, LTD.: COMPANY SNAPSHOT (2024)